LIVN (LivaNova) Moat Score: 6/10 (As of Jul. 02, 2026)


LIVN LivaNova PLC LIVN
76 GF Score
Price $83.61
GF Value $62.53
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is LivaNova Moat Score?

LivaNova LIVN +1.35% 76 Moat Score is 6 as of Jul. 02, 2026. GuruFocus rates LIVN with a GF Score™ of 76/100 and a GF Value™ of $62.53 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 846 Medical Devices & Instruments companies, LivaNova ranks better than 95.74% on this metric.

LivaNova has the Moat Score of 6, which implies that the company might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

LivaNova has Narrow Moat: LivaNova PLC has a strong position in the medical device industry, supported by valuable patents and consistent R&D. The company benefits from regulatory barriers and some pricing power, but intense competition limits its ability to establish a wide moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes LivaNova might have Narrow Moat - Strong narrow moat, clearly distinguishable but not wide.

LivaNova  (NAS:LIVN) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

LivaNova Moat Score Related Terms

LIVN vs IRTC, HAE, ITGR: Moat Score Comparison

For the Medical Devices subindustry, LivaNova's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LivaNova Moat Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, LivaNova's Moat Score distribution charts can be found below:

* The bar in red indicates where LivaNova's Moat Score falls into.


LIVN
76GF Score
LivaNova PLC LIVN
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 6 mean?
LivaNova (LIVN) has a Moat Score of 6 as of Jul. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, LivaNova ranks #36 out of 846 companies in the Medical Devices & Instruments industry, placing it in the top 4.3%.
Is LivaNova's Moat Score too high?
LivaNova's current Moat Score is 6. Based on the distribution chart, LivaNova ranks #36 out of 846 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, LivaNova has a GF Score™ of 76/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does LivaNova's Moat Score compare to IRTC and HAE?
According to the Medical Devices & Instruments industry distribution chart, LivaNova ranks #36 out of 846 companies for Moat Score. This places LivaNova in the top 4% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Devices & Instruments company?
A good Moat Score depends on the Medical Devices & Instruments industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. LivaNova's current Moat Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LivaNova stock overvalued right now?
Based on GuruFocus' analysis, LivaNova (LIVN) is currently considered Significantly Overvalued. The stock's GF Value™ is $62.53, compared to a current price of $83.61 — trading 33.7% above its estimated fair value. The current Moat Score is 6. LivaNova's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For LivaNova (LIVN), the current Moat Score is 6 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is LivaNova (LIVN) Overvalued in 2026?

Based on GuruFocus' analysis, LivaNova stock appears to be overvalued. The current stock price of $83.61 is trading 33.7% above its estimated GF Value™ of $62.53. GuruFocus considers LivaNova to be Significantly Overvalued.

Key valuation signals for LIVN:

  • Moat Score: 6
  • GF Value™: $62.53 vs. price of $83.61 (33.7% above fair value)
  • GF Score™: 76/100 with 7 warning signs

No single metric tells the full story. See the LIVN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

LivaNova Business Description

Other Exchanges LIA:Germany
Address 20 Eastbourne Terrace, London, GBR, W2 6LG
UK-based LivaNova was born of a combination of Cyberonics in the US and Sorin in Italy. The medical-device firm is primarily focused on cardiopulmonary solutions (with heart-lung machines and oxygenation equipment) as well as neuromodulation devices for treatment-resistant epilepsy and depression. Following the merger, LivaNova divested its cardiac rhythm management, heart valve, and extracorporeal membrane oxygenation businesses. It derives roughly half of its revenue from the US market, another 21% from Europe, and the remainder from the rest of the world.
76GF Score

Get the complete analysis for LIVN

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$83.61
Price
$62.53
GF Value